Levetiracetam Injection, Solution, Concentrate
Product Images NDC 72162-2638

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 72162-2638). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622638)

Levetiracetam Injection, USP 500 mg/5 mL (100 mg/mL) intravenous solution concentrate labeled by Bryant Ranch Prepack. The label indicates single-dose 5 mL vials, with a package of 10 vials. Manufactured by MSN Laboratories Private Limited. Includes storage instructions and dosage warnings.*

FDA Label Image

Levet-inj-figure-1 (Levet Inj Figure 1)

A vertical bar chart showing the percentage of patients across three groups: placebo, Levetiracetam 1000 mg/day, and Levetiracetam 3000 mg/day. The y-axis represents percentage of patients from 0% to 45%. The placebo group (N=95) shows 7.4%, Levetiracetam 1000 mg/day (N=97) shows 37.1%, and Levetiracetam 3000 mg/day (N=101) shows 39.6%.*

FDA Label Image

Levet-inj-figure-2 (Levet Inj Figure 2)

A vertical bar chart comparing the percentage of patients across three groups: Placebo, Levetiracetam 1000 mg/day, and Levetiracetam 2000 mg/day. The y-axis shows % of patients ranging from 0% to 45%, with percentages indicated above each bar: 6.3% for placebo, 20.8% for 1000 mg/day, and 35.2% for 2000 mg/day. Sample sizes for each group are noted below the x-axis categories.*

FDA Label Image

Levet-inj-figure-3 (Levet Inj Figure 3)

A bar chart comparing the percentage of patients between two groups: Placebo (N=104) and Levetiracetam 3000 mg/day (N=180). The y-axis shows percentage of patients from 0% to 40%. The Placebo group has a bar at 14.4%, while the Levetiracetam 3000 mg/day group has a higher bar at 39.4%, marked with an asterisk indicating statistical significance.*

FDA Label Image

Levet-inj-figure-4 (Levet Inj Figure 4)

A bar chart comparing the percentage of patients between two groups: Placebo (N=97) with 19.6% and Levetiracetam (N=101) with 44.6%. The y-axis represents the percentage of patients from 0% to 45%, and the x-axis labels the two groups.*

FDA Label Image

Levet-inj-figure-5 (Levet Inj Figure 5)

A bar graph comparing the percentage of patients between two groups: Placebo (N=51) with 19.6% and Levetiracetam (N=58) with 43.1%. The y-axis shows the percentage of patients from 0% to 45%. The bars illustrate a higher percentage for the Levetiracetam group than the placebo group.*

FDA Label Image

Levet-inj-figure-6 (Levet Inj Figure 6)

A bar graph comparing the percentage of patients in two groups: Placebo and Levetiracetam injection. The y-axis represents the percentage of patients from 0% to 100%. The Placebo group (N=84) shows 45.2%, and the Levetiracetam group (N=79) shows 72.2%, marked with an asterisk.*

FDA Label Image

Levet-inj-structure (Levet Inj Structure)

Chemical structure of levetiracetam, showing its molecular arrangement with a pyrrolidone ring, an amide group, and an ethyl side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.